208 related articles for article (PubMed ID: 2841880)
1. Safety of a live-attenuated Japanese encephalitis virus vaccine (SA14-14-2) for children.
Xin YY; Ming ZG; Peng GY; Jian A; Min LH
Am J Trop Med Hyg; 1988 Aug; 39(2):214-7. PubMed ID: 2841880
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of a Japanese encephalitis chimeric virus vaccine as a booster dose after primary vaccination with SA14-14-2 vaccine in Thai children.
Janewongwirot P; Puthanakit T; Anugulruengkitt S; Jantarabenjakul W; Phasomsap C; Chumket S; Yoksan S; Pancharoen C
Vaccine; 2016 Oct; 34(44):5279-5283. PubMed ID: 27628323
[TBL] [Abstract][Full Text] [Related]
3. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates.
Monath TP; Soike K; Levenbook I; Zhang ZX; Arroyo J; Delagrave S; Myers G; Barrett AD; Shope RE; Ratterree M; Chambers TJ; Guirakhoo F
Vaccine; 1999 Apr; 17(15-16):1869-82. PubMed ID: 10217584
[TBL] [Abstract][Full Text] [Related]
4. Immunizing children aged 9 to 15 months with live attenuated SA14-14-2 Japanese encephalitis vaccine in Thailand.
Chotpitayasunondh T; Sohn YM; Yoksan S; Min J; Ohrr H
J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S195-203. PubMed ID: 22043776
[TBL] [Abstract][Full Text] [Related]
5. [A large-scale study on the safety and epidemiological efficacy of Japanese encephalitis (JE) live vaccine (SA14-14-2) in the JE endemic areas].
Zhou B; Jia L; Xu X
Zhonghua Liu Xing Bing Xue Za Zhi; 1999 Feb; 20(1):38-41. PubMed ID: 10682513
[TBL] [Abstract][Full Text] [Related]
6. A randomized study of the immunogenicity and safety of Japanese encephalitis chimeric virus vaccine (JE-CV) in comparison with SA14-14-2 vaccine in children in the Republic of Korea.
Kim DS; Houillon G; Jang GC; Cha SH; Choi SH; Lee J; Kim HM; Kim JH; Kang JH; Kim JH; Kim KH; Kim HS; Bang J; Naimi Z; Bosch-Castells V; Boaz M; Bouckenooghe A
Hum Vaccin Immunother; 2014; 10(9):2656-63. PubMed ID: 25483480
[TBL] [Abstract][Full Text] [Related]
7. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
[TBL] [Abstract][Full Text] [Related]
8. Sero-Molecular Epidemiology of Japanese Encephalitis in Zhejiang, an Eastern Province of China.
Pan JR; Yan JY; Zhou JY; Tang XW; He HQ; Xie RH; Mao HY; Zhang YJ; Xie SY
PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004936. PubMed ID: 27560360
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety of inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children.
Chanthavanich P; Limkittikul K; Sirivichayakul C; Chokejindachai W; Hattasingh W; Pengsaa K; Surangsrirat S; Srisuwannaporn T; Kaewma B; Yoksan S; Jun G; Zhumu B
Hum Vaccin Immunother; 2018 Apr; 14(4):900-905. PubMed ID: 29227177
[TBL] [Abstract][Full Text] [Related]
10. Antigenic characterization of the live attenuated Japanese encephalitis vaccine virus SA14-14-2: a comparison with isolates of the virus covering a wide geographic area.
Wills MR; Sil BK; Cao JX; Yu YX; Barrett AD
Vaccine; 1992; 10(12):861-72. PubMed ID: 1455912
[TBL] [Abstract][Full Text] [Related]
11. A 5-year follow-up of antibody response in children vaccinated with single dose of live attenuated SA14-14-2 Japanese encephalitis vaccine: immunogenicity and anamnestic responses.
Sohn YM; Tandan JB; Yoksan S; Ji M; Ohrr H
Vaccine; 2008 Mar; 26(13):1638-43. PubMed ID: 18294743
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of Japanese encephalitis chimeric virus vaccine: Immune responses in children.
Chokephaibulkit K; Sirivichayakul C; Thisyakorn U; Pancharoen C; Boaz M; Bouckenooghe A; Feroldi E
Vaccine; 2016 Nov; 34(46):5664-5669. PubMed ID: 27686833
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of experimental live attenuated Japanese encephalitis vaccine viruses and comparison with wild-type strains using monoclonal and polyclonal antibodies.
Sil BK; Wills MR; Cao JX; Sharda R; Islam MA; Stagg DJ; Jennings AD; Gibson CA; Barrett AD
Vaccine; 1992; 10(5):329-33. PubMed ID: 1315470
[TBL] [Abstract][Full Text] [Related]
14. Primary and booster immune responses to SA14-14-2 Japanese encephalitis vaccine in Korean infants.
Sohn YM; Park MS; Rho HO; Chandler LJ; Shope RE; Tsai TF
Vaccine; 1999 May; 17(18):2259-64. PubMed ID: 10403593
[TBL] [Abstract][Full Text] [Related]
15. Phenotypic and genotypic characteristics of Japanese encephalitis attenuated live vaccine virus SA14-14-2 and their stabilities.
Yu Y
Vaccine; 2010 May; 28(21):3635-41. PubMed ID: 20226891
[TBL] [Abstract][Full Text] [Related]
16. Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine.
Yun KW; Lee HJ; Park JY; Cho HK; Kim YJ; Kim KH; Kim NH; Hong YJ; Kim DH; Kim HM; Cha SH
Vaccine; 2018 Mar; 36(11):1398-1404. PubMed ID: 29429815
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis.
Guirakhoo F; Zhang ZX; Chambers TJ; Delagrave S; Arroyo J; Barrett AD; Monath TP
Virology; 1999 May; 257(2):363-72. PubMed ID: 10329547
[TBL] [Abstract][Full Text] [Related]
18. Primary immunization of infants and toddlers in Thailand with Japanese encephalitis chimeric virus vaccine in comparison with SA14-14-2: a randomized study of immunogenicity and safety.
Feroldi E; Pancharoen C; Kosalaraksa P; Chokephaibulkit K; Boaz M; Meric C; Hutagalung Y; Bouckenooghe A
Pediatr Infect Dis J; 2014 Jun; 33(6):643-9. PubMed ID: 24717964
[TBL] [Abstract][Full Text] [Related]
19. Persistence of IgM Antibodies after Vaccination with Live Attenuated Japanese Encephalitis Vaccine.
Hills SL; Van Keulen A; Feser J; Panella A; Letson GW; Staples JE; Marfin AA; Brault AC
Am J Trop Med Hyg; 2020 Nov; 104(2):576-579. PubMed ID: 33236716
[TBL] [Abstract][Full Text] [Related]
20. Japanese encephalitis vaccines: current vaccines and future prospects.
Monath TP
Curr Top Microbiol Immunol; 2002; 267():105-38. PubMed ID: 12082985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
